NO167662B - 4-substituted-2-azetidinone. - Google Patents

4-substituted-2-azetidinone. Download PDF

Info

Publication number
NO167662B
NO167662B NO870289A NO870289A NO167662B NO 167662 B NO167662 B NO 167662B NO 870289 A NO870289 A NO 870289A NO 870289 A NO870289 A NO 870289A NO 167662 B NO167662 B NO 167662B
Authority
NO
Norway
Prior art keywords
azetidinone
group
substituted
general formula
mmol
Prior art date
Application number
NO870289A
Other languages
Norwegian (no)
Other versions
NO167662C (en
NO870289L (en
Inventor
Toshinari Tamura
Hidenori Iwamoto
Makoto Yoshida
Minoru Yamamoto
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP58048989A external-priority patent/JPS59225182A/en
Priority claimed from JP58221470A external-priority patent/JPS60115578A/en
Priority claimed from JP58221469A external-priority patent/JPS60115577A/en
Priority claimed from NO841158A external-priority patent/NO158740C/en
Publication of NO870289L publication Critical patent/NO870289L/en
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Priority to NO870289A priority Critical patent/NO167662C/en
Publication of NO167662B publication Critical patent/NO167662B/en
Publication of NO167662C publication Critical patent/NO167662C/en

Links

Description

Foreliggende oppfinnelse angår nye 4-substituerte 2-azetidinonforbindelser av generell formel VII The present invention relates to new 4-substituted 2-azetidinone compounds of general formula VII

hvori R g betegner et hydrogenatom, en laverealkylgruppe eller en aralkylgruppe, eller et salt derav. wherein R g denotes a hydrogen atom, a lower alkyl group or an aralkyl group, or a salt thereof.

Eksempler på den laverealkylgruppe vist ved R i den foregående generelle formel VII er rettkjedede eller forgre-nede alkylgrupper med 1 til 5, fortrinnsvis 1 til 3 carbon-atomer slik som en methylgruppe, en ethylgruppe, en propyl-gruppe, en butylgruppe, en pentylgruppe, en isopropylgruppe etc, og eksempler på aralkylgruppene vist ved R oer aryl-laverealkylgrupper slik som en benzylgruppe, en fenethylgruppe, en nafthylmethylgruppe etc. Examples of the lower alkyl group shown by R in the preceding general formula VII are straight-chain or branched alkyl groups with 1 to 5, preferably 1 to 3 carbon atoms such as a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group , an isopropyl group, etc., and examples of the aralkyl groups shown by R are aryl-lower alkyl groups such as a benzyl group, a phenethyl group, a naphthylmethyl group, etc.

De nye forbindelser vist ved generell formel VII er anvendbare som mellomprodukter for fremstilling av terapeutisk aktive forbindelser vist ved generell formel I som beskrevet i norsk patent 158 740. The new compounds shown by general formula VII are usable as intermediates for the production of therapeutically active compounds shown by general formula I as described in Norwegian patent 158 740.

Forbindelsen vist ved generell formel VII kan fremstilles ved omsetning av en carboxylsyre vist ved formel The compound shown by general formula VII can be prepared by reacting a carboxylic acid shown by formula

eller et reaktivt derivat derav, og et amin av generell formel hvori R o har den ovenfor angitte betydning, eller et reaktivt derivat derav. Reaksjonen er en peptidsyntesereaksjon og kan utføres på kjent måte. Ennvidere angår oppfinnelsen nye 4-substituerte 2-azetidinonforbindelser av generell formel 9 hvori R betegner or a reactive derivative thereof, and an amine of general formula in which R o has the above meaning, or a reactive derivative thereof. The reaction is a peptide synthesis reaction and can be carried out in a known manner. Furthermore, the invention relates to new 4-substituted 2-azetidinone compounds of general formula 9 in which R denotes

og fremgangsmåte for fremstilling av disse. and method for producing these.

Den foregående forbindelse er anvendbar som et mellomprodukt for fremstilling av forbindelsene av formel VII, dg er ennvidere anvendbar som mellomprodukt for fremstilling av g-lactamserier av antibiotika. The preceding compound is usable as an intermediate for the preparation of the compounds of formula VII, dg is also usable as an intermediate for the preparation of γ-lactam series of antibiotics.

Det nye mellomproduktet fremstilles ved omsetning av en carboxylsyre av formel The new intermediate is produced by reacting a carboxylic acid of formula

eller et reaktivt derivat derav og pentaklorfenol eller N-hydroxysuccinimid. or a reactive derivative thereof and pentachlorophenol or N-hydroxysuccinimide.

Reaksjonen er en estersyntesereaksjon og en kjent The reaction is an ester synthesis reaction and a known one

forestringsmetode kan hensiktsmessig velges. esterification method can be suitably chosen.

Oppfinnelsen illustreres ytterligere ved de etter-følgende eksempler. The invention is further illustrated by the following examples.

De forkortelser som anvendes i eksemplene har føl-gende betydning: The abbreviations used in the examples have the following meaning:

TLC Tynnskiktskromatografi TLC Thin layer chromatography

NMR Kjernemagnetisk resonansspektrum NMR Nuclear magnetic resonance spectrum

IR Infrarød absorpsjonsspektrum Masse' Masseanalysespektrum IR Infrared absorption spectrum Mass' Mass analysis spectrum

Z Benzyloxycarbonyl Z Benzyloxycarbonyl

Bn Benzyl Bn Benzyl

His Histidin His Histidine

Pro Prolin Pro Proline

DNP 2,4-dinitrofenyl DNP 2,4-dinitrophenyl

Ts Tosyl TS Tosyl

BOC t-butyloxycarbonyl BOC t-butyloxycarbonyl

DMF Dimethylformamid DMF Dimethylformamide

HOBT N-hydroxy-1,2,3-benzotriazol HOBT N-hydroxy-1,2,3-benzotriazole

DCC Dicyclohexylcarbodiimid DCC Dicyclohexylcarbodiimide

THF tetrahydrofuran THF tetrahydrofuran

HOSu N-hydroxysuccinimid HOSu N-Hydroxysuccinimide

Ph Fenyl Ph Phenyl

Eksempel 1 Example 1

I 200 ml DMF ble oppløst 10 g (8,68 mmol) (S)-2-azetidinon-4-carboxylsyre (2) og 24,4 g (8,68 mmol) pentaklorfenol hvoretter 17,93 g (8,70 mmol) DCC ble tilsatt til løs-ningen under avkjøling (0 til 5°C).. Etter omrøring av blandingen i 5 timer ved romtemperatur ble det utfelte dicyclo-hexylurea filtrert fra og filtratet ble konsentrert under redusert trykk. Det dannede residuum ble oppløst i 200 ml ethylacetat ved oppvarmning og ble deretter avkjølt. De utfelte krystaller ble oppsamlet ved filtrering under dannelse av 25,6 g gulaktige krystaller av (S)-4-pentaklorfenoxycarbonyl-2-azetidinon (58) med et smeltepunkt på 177 til 179°C. 10 g (8.68 mmol) of (S)-2-azetidinone-4-carboxylic acid (2) and 24.4 g (8.68 mmol) of pentachlorophenol were dissolved in 200 ml of DMF, after which 17.93 g (8.70 mmol ) DCC was added to the solution under cooling (0 to 5°C).. After stirring the mixture for 5 hours at room temperature, the precipitated dicyclohexylurea was filtered off and the filtrate was concentrated under reduced pressure. The residue formed was dissolved in 200 ml of ethyl acetate by heating and was then cooled. The precipitated crystals were collected by filtration to give 25.6 g of yellowish crystals of (S)-4-pentachlorophenoxycarbonyl-2-azetidinone (58) with a melting point of 177 to 179°C.

NMR (90 MHz, d<6->DMSO-D20) <6>ppm: 3,23 (1.H, q, azetidinonring 3-stilling), 3,57 (1H, q, azetidinonring 3-stilling), 4,70 (1H, q, azetidinonring 4-stilling) NMR (90 MHz, d<6->DMSO-D2O) <6>ppm: 3.23 (1.H, q, azetidinone ring 3-position), 3.57 (1H, q, azetidinone ring 3-position), 4 .70 (1H, q, azetidinone ring 4-position)

IR (KBr) cm"<1>: 3200, 1775, 1755, 1720 IR (KBr) cm"<1>: 3200, 1775, 1755, 1720

Masse: 363 (M<+>), 335, 266, 237 Mass: 363 (M<+>), 335, 266, 237

Eksempel 2 Example 2

I 20 ml DMF ble oppløst 690 mg (S)-2-azetidinon-4-carboxylsyre (2) og etter tilsetning av 690 mg HOSu og 1,236 g DCC under isavkjøling fikk reaksjonen forløpe i 30 minutter under isavkjøling og deretter i 4 timer ved romtemperatur. Uløselige bestanddeler ble filtrert fra reaksjonsblandingen hvoretter løsningsmidlet ble destillert fra under dannelse av et lysebrunt, fast materiale. Produktet ble omkrystallisert fra dioxan-petroleumether (5:1) under dannelse av 7 50 mg (S)-4-(2,5-dioxopyrrolidin-1-yl)-oxycarbonyl-2-azetidinon. 690 mg of (S)-2-azetidinone-4-carboxylic acid (2) was dissolved in 20 ml of DMF and after adding 690 mg of HOSu and 1.236 g of DCC under ice cooling, the reaction was allowed to proceed for 30 minutes under ice cooling and then for 4 hours at room temperature . Insolubles were filtered from the reaction mixture after which the solvent was distilled off to give a light brown solid. The product was recrystallized from dioxane-petroleum ether (5:1) to give 750 mg of (S)-4-(2,5-dioxopyrrolidin-1-yl)-oxycarbonyl-2-azetidinone.

NMR (DMSO-d<6>, TMS) Sppm: 8,70 (bred, 1H), 4,62 (dd, 1H), NMR (DMSO-d<6>, TMS) Spppm: 8.70 (broad, 1H), 4.62 (dd, 1H),

3,84 (s, 4H) 3.84 (s, 4H)

IR (KBr) cm<-1>: 3320, 2920, 2840, 1810, 1780, 1750, 1730, IR (KBr) cm<-1>: 3320, 2920, 2840, 1810, 1780, 1750, 1730,

1720, 1650, 1620, 1570 1720, 1650, 1620, 1570

Masse (CI i stråle): 213 (M+ + 1), 185, 171, 116 Mass (CI in beam): 213 (M+ + 1), 185, 171, 116

Eksempel 3 Example 3

I 75 ml DMF ble suspendert 6,05 g (25 mmol) L-histi-dinmethylester-2-hydroklorid (59) og etter avkjøling av suspensjonen til 0 til 5°C ble 5,05 g (50 mmol) triethylamin langsomt, dråpevis tilsatt til suspensjonen. Deretter ble blandingen omrørt i 15 minutter ved samme temperatur. In 75 ml DMF was suspended 6.05 g (25 mmol) L-histidine methyl ester-2-hydrochloride (59) and after cooling the suspension to 0 to 5°C 5.05 g (50 mmol) triethylamine was added slowly, dropwise added to the suspension. The mixture was then stirred for 15 minutes at the same temperature.

9,50 g (25 mmol) av forbindelse (58) ble tilsatt til blandingen som et pulver, og etter omrøring av blandingen i 9.50 g (25 mmol) of compound (58) was added to the mixture as a powder, and after stirring the mixture in

én time ved samme temperatur fikk blandingen stå over natten ved romtemperatur. Triethylaminhydroklorid ble filtrert fra, filtratet ble konsentrert under redusert trykk. Residuet ble blandet med 4 0 ml ethylacetat og 30 ml vann etterfulgt av risting, hvoretter det vandige lag ble oppsamlet. Ethylace-tatlaget ble ekstrahert to ganger med 20 ml vann. Det vandige lag ble kombinert og vannet ble destillert fra under redusert trykk. Residuet ble blandet med acetonitril og benzen og blandingen ble konsentrert under redusert trykk. Residuet ble krystallisert fra 30 ml methanol og krystallene ble opp- one hour at the same temperature, the mixture was allowed to stand overnight at room temperature. Triethylamine hydrochloride was filtered off, the filtrate was concentrated under reduced pressure. The residue was mixed with 40 ml of ethyl acetate and 30 ml of water followed by shaking, after which the aqueous layer was collected. The ethylacetate layer was extracted twice with 20 ml of water. The aqueous layers were combined and the water was distilled off under reduced pressure. The residue was mixed with acetonitrile and benzene and the mixture was concentrated under reduced pressure. The residue was crystallized from 30 ml of methanol and the crystals were

samlet under dannelse av 4,1 g av f arveløse krystaller av N<01->collected to give 4.1 g of f heirless crystals of N<O1->

[(S)-2-a2etidinon-4-carbonyl]-L-histidinmethylester (60) med smeltepunkt på 142 til 14 7°c. [(S)-2-α2etidinone-4-carbonyl]-L-histidine methyl ester (60) mp 142 to 147°C.

NMR (90 MHz, d<6->DMSO) 6ppm: 2,94 (2H, d, 6-stilling methylen av histidingruppe), 3,60 (3H, s, methylgruppe), 4,02 (1H, q, azetidinonring 4-stilling), 4,54 (1H, m, a-stilling methin av histidingruppe), 6,72 (1H, s, imidazolring), 7,56 (1H, s, imidazolring), 8,20 (Hf, s, NH) , 8,56 (1H, d, azetidinonring NH) NMR (90 MHz, d<6->DMSO) 6ppm: 2.94 (2H, d, 6-position methylene of histidine group), 3.60 (3H, s, methyl group), 4.02 (1H, q, azetidinone ring 4-position), 4.54 (1H, m, a-position methine of histidine group), 6.72 (1H, s, imidazole ring), 7.56 (1H, s, imidazole ring), 8.20 (Hf, s , NH) , 8.56 (1H, d, azetidinone ring NH)

IR (KBr) cm"<1>: 3250, 3100, 2950, 1770, 1750, 1740, 1720, IR (KBr) cm"<1>: 3250, 3100, 2950, 1770, 1750, 1740, 1720,

1650, 1550 1650, 1550

Eksempel 4 Example 4

I 20 ml kloroform ble oppløst 1,178 g (2 mmol) histidinbenzylester.2-p-toluensulfonat hvoretter 404 mg (2 mmol) triethylamin ble langsomt tilsatt til løsningen under isavkjøling til 0°C. Til løsningen ble tilsatt 766 mg (2 mmol) (S)-4-pentaklorfenoxycarbonyl-2-azetidinon (58) som et pulver og blandingen ble omrørt over natten ved 0 til 5°C. 1.178 g (2 mmol) of histidine benzyl ester, 2-p-toluenesulfonate were dissolved in 20 ml of chloroform, after which 404 mg (2 mmol) of triethylamine was slowly added to the solution under ice-cooling to 0°C. To the solution was added 766 mg (2 mmol) of (S)-4-pentachlorophenoxycarbonyl-2-azetidinone (58) as a powder and the mixture was stirred overnight at 0 to 5°C.

Til reaksjonsblandingen ble tilsatt 30 ml kloroform og det ønskede produkt ble ekstrahert to ganger, hver gang med 3 0 ml vann. Deretter ble vannet destillert fra under redusert trykk og det dannede residuum ble azeotropisk dehydrert med benzen-acetonitril under dannelse av et farveløst, klebrig produkt. Produktet ble underkastet silicagelkolonnekromatografi under anvendelse av 50 ml Wako-gel C-200 og eluert med ethylacetat-methanol-konsentrert, vandig ammoniakk (60:30:3) under dannelse av 470 mg N et- [(S)-2-azetidinon-4-carbonyl]-L-histidinbenzyl-ester (60-1) med smeltepunkt på 196 til 199°C som farveløse krystaller. To the reaction mixture was added 30 ml of chloroform and the desired product was extracted twice, each time with 30 ml of water. Then the water was distilled off under reduced pressure and the resulting residue was azeotropically dehydrated with benzene-acetonitrile to form a colorless sticky product. The product was subjected to silica gel column chromatography using 50 ml of Wako gel C-200 and eluted with ethyl acetate-methanol-concentrated aqueous ammonia (60:30:3) to give 470 mg of N et-[(S)-2-azetidinone- 4-carbonyl]-L-histidine benzyl ester (60-1) mp 196 to 199°C as colorless crystals.

NMR (90 MHz, d<6->DMSO) 6ppm: 2/58 MH' m' azetidinonring 3-stilling), 2,96 (2H, d, histidingruppe 6-stilling methylen), 3,12 (1H, m, azetidinonring 3-stilling), 4,00 (1H, m, azetidinonring 4-stilling), 4,62 (1H, NMR (90 MHz, d<6->DMSO) 6ppm: 2/58 MH' m' azetidinone ring 3-position), 2.96 (2H, d, histidine group 6-position methylene), 3.12 (1H, m, azetidinone ring 3-position), 4.00 (1H, m, azetidinone ring 4-position), 4.62 (1H,

m, histidingruppe a-stilling methin), 5,10 (2H, s, benzylstilling), 6,80 (1H, s, imidazolring), 7,36 (5H, s, benzenring), 7,56 (1H, s, imidazolring), 8,20 (1H, s, NH), 8,58 (1H, d, NH) m, histidine group a-position methine), 5.10 (2H, s, benzyl position), 6.80 (1H, s, imidazole ring), 7.36 (5H, s, benzene ring), 7.56 (1H, s, imidazole ring), 8.20 (1H, s, NH), 8.58 (1H, d, NH)

IR (KBr) cm"<1>: 3260, 2980, 2760, 1750, 1650, 1540 IR (KBr) cm"<1>: 3260, 2980, 2760, 1750, 1650, 1540

Claims (2)

1. 4-substituerte 2-azetidinonforbindelser, karakterisert ved at de har generell formel (VII) hvori R8 betegner et hydrogenatom, en laverealkylgruppe eller en aralkylgruppe, eller et salt derav.1. 4-substituted 2-azetidinone compounds, characterized in that they have general formula (VII) in which R8 denotes a hydrogen atom, a lower alkyl group or an aralkyl group, or a salt thereof. 2. 4-substituerte 2-azetidinonforbindelser, karakterisert ved at de har generell formel (X) 9 hvori R betegner2. 4-substituted 2-azetidinone compounds, characterized in that they have general formula (X) 9 in which R denotes
NO870289A 1983-03-25 1987-01-23 4-substituted-2-azetidinone. NO167662C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO870289A NO167662C (en) 1983-03-25 1987-01-23 4-substituted-2-azetidinone.

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP58048989A JPS59225182A (en) 1983-03-25 1983-03-25 Derivative of 2-azetidinone-4-carboxylic acid
JP58221470A JPS60115578A (en) 1983-11-25 1983-11-25 2-azetidinone-4-substituted compound
JP58221469A JPS60115577A (en) 1983-11-25 1983-11-25 2-azetidinone-4-substitution product
NO841158A NO158740C (en) 1983-03-25 1984-03-23 ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE 4-SUBSTITUTED 2-AZETIDINONE COMPOUNDS.
NO870289A NO167662C (en) 1983-03-25 1987-01-23 4-substituted-2-azetidinone.

Publications (3)

Publication Number Publication Date
NO870289L NO870289L (en) 1984-09-26
NO167662B true NO167662B (en) 1991-08-19
NO167662C NO167662C (en) 1991-11-27

Family

ID=27522766

Family Applications (1)

Application Number Title Priority Date Filing Date
NO870289A NO167662C (en) 1983-03-25 1987-01-23 4-substituted-2-azetidinone.

Country Status (1)

Country Link
NO (1) NO167662C (en)

Also Published As

Publication number Publication date
NO167662C (en) 1991-11-27
NO870289L (en) 1984-09-26

Similar Documents

Publication Publication Date Title
EP0354583B1 (en) DC-88A derivatives
NO329020B1 (en) difluoropyridine
US6048864A (en) Quinolines and quinazolines useful in therapy
US4987232A (en) Preparation of 2-chloropyridine 3-carboxylic acid esters
US4684662A (en) Disubstituted proline derivatives
SU888815A3 (en) Method of preparing nitrocompound
GB2213146A (en) Pyrimidine derivatives
KR20210151056A (en) Method for preparing DON prodrug from L-pyroglutamic acid
US4032559A (en) N,2-dicyanoacetimidates
US4703051A (en) 4,7-dihydrothieno[2,3-B]pyridine derivatives useful in the treatment of cardiovascular diseases
US5856495A (en) Process for the preparation of triazolinone herbicides
HU182636B (en) Process for producing pyrazolo-imidazol derivatives
US5968967A (en) Pyrazolones derivatives
US4734508A (en) Process and intermediates for preparing 4-substituted proline derivatives
NO167662B (en) 4-substituted-2-azetidinone.
FI66853B (en) MELLAN PRODUCTS FOR ANALYZING THE HYPOTENSIVE 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -6,7-DIMETOXYQUINAZOLINE
US5112855A (en) Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds and compositions
CA2149007C (en) Cyclohexane derivatives, process for their preparation, and the use of the compounds for the treatment of diseases
MXPA02000316A (en) Benzofurane derivatives.
US5126455A (en) Preparation of substituted alkali metal piperidine-4-carboxylates
Takiguchi et al. Antifungal Activities of α-Isocyano-β-phenylpropionamides
EP0132964A2 (en) 2-Azabicyclo[2.2.2]octane derivatives
EP0602458A1 (en) 1,4-Benzoxazine derivatives
Selby et al. Synthesis and structure elucidation of 3‐methoxy‐1‐methyl‐1H‐1, 2, 4,‐triazol‐5‐amine and 5‐methoxy‐1‐methyl‐1H‐1, 2, 4,‐triazol‐3‐amine
JP3459270B2 (en) Preparation of N-tert-butoxycarbonyl-maleimide